Pioneering smarter, faster ways to unlock treatments for unmet medical needs.
The shortest path to discovery starts here.
What we do
MassAffinity empowers pharmaceutical and biotechnology partners to accelerate drug discovery for undruggable and complex targets through our proprietary Collision Activated Rapid Mass Spectrometry (CARMS) platform.
CARMS delivers faster, more reliable insights than traditional methods, enabling partners to de-risk early-stage development and unlock new treatment opportunities for unmet medical needs.
‘Where others see biological complexity, we see therapeutic opportunity.’
Dr Spencer Gu, Scientific Co-founder
How it works
We use next-generation technology to cut through biological complexity and uncover real interactions, unlocking new treatments for diseases that traditional drug discovery leaves behind.
Explore Our Technology
From sample to hit identification at unmatched speed
10× faster than traditional affinity selection workflows
Traditional Workflow
Takes months to years, complex multi-step processes, limited insights
CARMS Workflow
Completed in weeks, single workflow, real-world results
Traditional discovery relies on protein purification, custom assays, and oversimplified systems that slow progress and miss what matters.
CARMS changes that.
MassAffinity reveals drug–target interactions directly in native biological systems — no purification, assays, or artificial models required.
By embracing biological complexity, CARMS accelerates discovery and brings clarity to even the most challenging targets.
Why MassAffinity?
Built for complexity. Designed for speed.
We have built a platform that meets the reality of today’s discovery challenges.
Faster
Smarter
More Reliable
More Accessible
Built for today
Our Discovery Capabilities
Two pathways. One mission: unlocking better treatments, faster
Drug Discovery Enablement
Built to help discovery teams rapidly move through complexity and uncover true potential.
- Understand how a compound works (MoA)
- Find new hits for complex, multifactorial diseases
- Explore undruggable or hard-to-assay targets
- Expand lead series quickly
- Accelerate hit ID when time and tools are limited
Therapeutic Advancement and Discovery
Driving internal innovation in areas of high unmet need.
- Complex, multifactorial diseases
- Neurodegenerative conditions
- Women’s health
- Personalised and precision medicine
- Systems biology innovation
Discovery in Action
Real-world discovery challenges solved with CARMS.
Kir4.2 Ion Channel
Identified a new small-molecule binder for a difficult-to-study ion channel without the need for purified protein
TRPM2 Membrane Protein
Detected known and novel ligands for a traditionally undruggable membrane protein under native conditions.
CARMS Screening in Cell Lysates
Identified active compounds directly in complex cell lysates without custom assay development.
Partner with Us
Let’s move faster, together
Ready to accelerate your discovery program?
Work with MassAffinity to de-risk early-stage discovery, explore undruggable targets or validate your AI predictions.
Custom projects and collaboration models available.